Literature DB >> 17436229

Anti-tumor necrosis factor-alpha treatment activates Borrelia burgdorferi spirochetes 4 weeks after ceftriaxone treatment in C3H/He mice.

Heta Yrjänäinen1, Jukka Hytönen, Xiao-yu R Song, Jarmo Oksi, Kaija Hartiala, Matti K Viljanen.   

Abstract

BACKGROUND: The effect of anti-tumor necrosis factor (TNF)-alpha treatment in Borrelia burgdorferi-infected and ceftriaxone-treated C3H/He mice was evaluated.
METHODS: Mice were infected with B. garinii A218 or B. burgdorferi sensu stricto N40. At 2 weeks of infection, one group was treated simultaneously with ceftriaxone and anti-TNF-alpha, whereas another received ceftriaxone at 2 weeks and anti-TNF-alpha 4 weeks later. One group received ceftriaxone treatment only. Infected and noninfected control groups were sham treated.
RESULTS: At 14 weeks of infection, B. burgdorferi could not be detected by cultivation or by polymerase chain reaction in tissue samples of any mouse treated with ceftriaxone only. However, spirochetes grew from the tissue samples of one-third of the mice treated with anti-TNF-alpha simultaneously or 4 weeks after ceftriaxone. These activated spirochetes showed ceftriaxone sensitivity rates, plasmid profiles, and virulence rates similar to those of bacteria used to infect the mice. All infected control mice and mice given anti-TNF-alpha only were culture positive.
CONCLUSIONS: This report shows that, after ceftriaxone treatment for 5 days, a portion of B. burgdorferi-infected mice still have live spirochetes in their body, which are activated by anti-TNF-alpha treatment.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17436229     DOI: 10.1086/513873

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  19 in total

1.  Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy.

Authors:  Linda K Bockenstedt; David G Gonzalez; Ann M Haberman; Alexia A Belperron
Journal:  J Clin Invest       Date:  2012-06-25       Impact factor: 14.808

Review 2.  Lyme arthritis: current concepts and a change in paradigm.

Authors:  Dean T Nardelli; Steven M Callister; Ronald F Schell
Journal:  Clin Vaccine Immunol       Date:  2007-11-14

3.  Psychiatric comorbidity and other psychological factors in patients with "chronic Lyme disease".

Authors:  Afton L Hassett; Diane C Radvanski; Steven Buyske; Shantal V Savage; Leonard H Sigal
Journal:  Am J Med       Date:  2009-09       Impact factor: 4.965

Review 4.  Antibiotic treatment of animals infected with Borrelia burgdorferi.

Authors:  Gary P Wormser; Ira Schwartz
Journal:  Clin Microbiol Rev       Date:  2009-07       Impact factor: 26.132

5.  Ineffectiveness of tigecycline against persistent Borrelia burgdorferi.

Authors:  Stephen W Barthold; Emir Hodzic; Denise M Imai; Sunlian Feng; Xiaohua Yang; Benjamin J Luft
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

Review 6.  Chronic Lyme disease: a review.

Authors:  Adriana Marques
Journal:  Infect Dis Clin North Am       Date:  2008-06       Impact factor: 5.982

7.  Persistence of Borrelia burgdorferi following antibiotic treatment in mice.

Authors:  Emir Hodzic; Sunlian Feng; Kevin Holden; Kimberly J Freet; Stephen W Barthold
Journal:  Antimicrob Agents Chemother       Date:  2008-03-03       Impact factor: 5.191

8.  Viable Borrelia burgdorferi enhances interleukin-10 production and suppresses activation of murine macrophages.

Authors:  John J Lazarus; Maria A Kay; Akisha L McCarter; R Mark Wooten
Journal:  Infect Immun       Date:  2007-12-17       Impact factor: 3.441

9.  Lyme disease: the next decade.

Authors:  Raphael B Stricker; Lorraine Johnson
Journal:  Infect Drug Resist       Date:  2011-01-07       Impact factor: 4.003

10.  Review of evidence for immune evasion and persistent infection in Lyme disease.

Authors:  Keith Berndtson
Journal:  Int J Gen Med       Date:  2013-04-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.